Evaluation of GS-0151 in Patients With Rheumatoid Arthritis: A Clinical Trial

The primary objective of this study is to evaluate the efficacy and safety of **GS-0151** in participants diagnosed with **Rheumatoid Arthritis**. This is clinically relevant as it aims to determine the potential of GS-0151 to improve patient outcomes in managing this chronic inflammatory disorder, which can lead to joint damage and disability if not effectively treated.

The clinical trial involves a total of **75 participants** diagnosed with **Rheumatoid Arthritis**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, and there are no specific lifestyle considerations such as diet or physical activity mentioned. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of a new investigational product in participants diagnosed with **Rheumatoid Arthritis**. This study is a Phase 3, randomized, double-blind, controlled trial, which aims to provide robust data on the therapeutic potential of the investigational product. The trial is expected to commence recruitment on August 8, 2025, and is projected to conclude by January 22, 2027. Participants will be randomly assigned to either the investigational product group or a control group, ensuring that neither the participants nor the investigators are aware of the group assignments, thus maintaining the integrity of the double-blind design.

The sequence of study visits is structured to ensure comprehensive data collection and participant safety. Initially, an inclusion (screening) visit will be conducted to assess eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and any potential adverse effects. These visits will include clinical assessments, laboratory tests, and questionnaires to evaluate the impact of the treatment on disease symptoms and quality of life. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to gather data on the long-term effects of the treatment.

The expected length of participant involvement in the trial is approximately 18 months, encompassing the initial screening, treatment period, and follow-up assessments. Conditions that may lead to early termination from the study include the occurrence of serious adverse events, withdrawal of consent by the participant, or any other medical or ethical reasons deemed necessary by the investigators. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 8, 2025, with an estimated completion date of January 22, 2027. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The study will focus on evaluating the therapeutic impact of the investigational product, with efficacy outcomes being a critical component of the trial's objectives. The trial's design will incorporate validated methodologies to ensure the reliability and validity of the efficacy data collected throughout the study period.